Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Prerna Infrabuild Ltd. Share Price

₹ 26.01 0.04 (0.15%)

Apr 15 2025 03:28 PM Realty NSE: PRERINFRA

Prerna Infrabuild Ltd. Share Price Update

As of the latest trading session, Prerna Infrabuild Ltd. share price is currently at 26.01, which is up by 0.04 from its previous closing. Today, the stock has fluctuated between 26.00 and 27.24. Over the past year, Prerna Infrabuild Ltd. has achieved a return of -12.58 %. In the last month alone, the return has been 6.87 %. Read More...

Prerna Infrabuild Ltd. Performance

Day Range

Low26.00 High27.24

26.25

52 Week Range

Low 22.11 High 50.99

26.25

Prerna Infrabuild Ltd. Share Price

531802

PRERINFRA

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

26.70 Prev. Close

25.97 Volume (Shares)

11976.00

Total traded value

3.14 Upper Circuit

31.50 Lower Circuit

21.00

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Prerna Infrabuild Ltd. Fundamentals

(Standalone)

Market Cap (Cr)	93.96
PE Ratio (TTM)	38.19
Book Value / Share	28.44
Beta	0.79

ROE	6.99%
EPS (TTM)	0.68
Dividend Yield	0.00%
Net Profit Qtr (Cr)	-0.40

Prerna Infrabuild Ltd. Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	0.00
Operating Expense	0.58
Net Profit	-0.40
Net Profit Margin (%)	0.00
Earnings Per Share (EPS)	-0.11
EBITDA	-0.28
Effective Tax Rate (%)	-29.03

Particulars	SEP 2024 (Values in Cr)
Revenue	0.01
Operating Expense	0.80
Net Profit	0.50
Net Profit Margin (%)	5000.00
Earnings Per Share (EPS)	0.14
EBITDA	0.24
Effective Tax Rate (%)	-149.99

Particulars	JUN 2024 (Values in Cr)
Revenue	1.32
Operating Expense	0.73
Net Profit	1.14
Net Profit Margin (%)	86.36
Earnings Per Share (EPS)	0.32
EBITDA	1.62
Effective Tax Rate (%)	26.92

Particulars	MAR 2024 (Values in Cr)
Revenue	17.35
Operating Expense	15.87
Net Profit	1.20
Net Profit Margin (%)	6.91
Earnings Per Share (EPS)	0.33
EBITDA	2.21
Effective Tax Rate (%)	44.65

Particulars	DEC 2023 (Values in Cr)
Revenue	0.85
Operating Expense	0.93
Net Profit	0.54
Net Profit Margin (%)	63.52
Earnings Per Share (EPS)	0.15
EBITDA	0.80
Effective Tax Rate (%)	27.02

Particulars	MAR 2024 (Values in Cr)
Revenue	23.82
Operating Expense	19.30
Net Profit	5.21
Net Profit Margin (%)	21.87
Earnings Per Share (EPS)	1.44
EBITDA	7.16
Effective Tax Rate (%)	24.12

Particulars	MAR 2023 (Values in Cr)
Revenue	17.86
Operating Expense	6.26
Net Profit	9.89
Net Profit Margin (%)	55.37
Earnings Per Share (EPS)	8.21
EBITDA	12.34
Effective Tax Rate (%)	17.80

Particulars	MAR 2022 (Values in Cr)
Revenue	23.21
Operating Expense	16.09
Net Profit	5.87
Net Profit Margin (%)	25.29
Earnings Per Share (EPS)	4.87
EBITDA	7.64
Effective Tax Rate (%)	18.92

Particulars	MAR 2021 (Values in Cr)
Revenue	3.92
Operating Expense	4.21
Net Profit	-0.14
Net Profit Margin (%)	-3.57
Earnings Per Share (EPS)	-0.12
EBITDA	0.33
Effective Tax Rate (%)	22.22

Particulars	MAR 2020 (Values in Cr)
Revenue	9.75
Operating Expense	10.32
Net Profit	0.04
Net Profit Margin (%)	0.41
Earnings Per Share (EPS)	0.01
EBITDA	0.56
Effective Tax Rate (%)	42.85

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	28.04
ROE %	7.22
ROCE %	7.87
Total Debt to Total Equity	0.48
EBITDA Margin	19.69

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	39.82
ROE %	22.64
ROCE %	19.98
Total Debt to Total Equity	0.44
EBITDA Margin	69.65

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	31.85
ROE %	16.57
ROCE %	20.17
Total Debt to Total Equity	0.02
EBITDA Margin	32.25

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	26.98
ROE %	-0.43
ROCE %	-0.30
Total Debt to Total Equity	0.04
EBITDA Margin	7.37

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	27.10
ROE %	0.03
ROCE %	0.39
Total Debt to Total Equity	0.03
EBITDA Margin	5.53

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	27.99
ROE %	6.99
ROCE %	7.81
Total Debt to Total Equity	0.19
EBITDA Margin	30.02

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	39.82
ROE %	22.66
ROCE %	22.74
Total Debt to Total Equity	0.22
EBITDA Margin	68.59

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	31.85
ROE %	16.57
ROCE %	20.21
Total Debt to Total Equity	0.02
EBITDA Margin	32.96

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	26.98
ROE %	-0.43
ROCE %	-0.30
Total Debt to Total Equity	0.03
EBITDA Margin	8.44

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	27.10
ROE %	0.03
ROCE %	0.39
Total Debt to Total Equity	0.03
EBITDA Margin	5.56

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	27.30
Total Assets	138.52
Total Liabilities	138.52
Total Equity	101.31
Share Outstanding	36127500
Price to Book Ratio	1.07
Return on Assets (%)	3.76
Return on Capital (%)	3.84

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	9.65
Total Assets	86.75
Total Liabilities	86.75
Total Equity	47.95
Share Outstanding	12042500
Price to Book Ratio	0.78
Return on Assets (%)	11.26
Return on Capital (%)	11.47

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	4.21
Total Assets	43.41
Total Liabilities	43.41
Total Equity	38.36
Share Outstanding	12042510
Price to Book Ratio	0.93
Return on Assets (%)	13.51
Return on Capital (%)	15.09

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	2.41
Total Assets	39.26
Total Liabilities	39.26
Total Equity	32.49
Share Outstanding	12042510
Price to Book Ratio	0.67
Return on Assets (%)	-0.36
Return on Capital (%)	-0.43

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	3.61
Total Assets	40.39
Total Liabilities	40.39
Total Equity	32.63
Share Outstanding	12042510
Price to Book Ratio	0.70
Return on Assets (%)	0.01
Return on Capital (%)	0.02

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	17.37
Total Assets	111.32
Total Liabilities	111.32
Total Equity	101.13
Share Outstanding	36127500
Price to Book Ratio	1.07
Return on Assets (%)	4.68
Return on Capital (%)	4.71

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	8.08
Total Assets	66.37
Total Liabilities	66.37
Total Equity	47.95
Share Outstanding	12042510
Price to Book Ratio	0.78
Return on Assets (%)	14.72
Return on Capital (%)	14.75

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	4.21
Total Assets	43.41
Total Liabilities	43.41
Total Equity	38.36
Share Outstanding	12042510
Price to Book Ratio	0.93
Return on Assets (%)	13.52
Return on Capital (%)	15.22

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	2.41
Total Assets	39.11
Total Liabilities	39.11
Total Equity	32.49
Share Outstanding	12042510
Price to Book Ratio	0.67
Return on Assets (%)	-0.36
Return on Capital (%)	-0.43

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	3.60
Total Assets	40.07
Total Liabilities	40.07
Total Equity	32.63
Share Outstanding	12042510
Price to Book Ratio	0.70
Return on Assets (%)	0.01
Return on Capital (%)	0.02

Particulars	MAR 2024 (Values in Cr)
Net Income	0.00
Cash from Operations	-10.84
Cash from Investing	-29.68
Cash from Financing	43.48
Net change in Cash	1.09
Free Cash Flow	-10.29

Particulars	MAR 2023 (Values in Cr)
Net Income	11.90
Cash from Operations	-11.64
Cash from Investing	12.16
Cash from Financing	-0.67
Net change in Cash	-2.05
Free Cash Flow	-11.40

Particulars	MAR 2022 (Values in Cr)
Net Income	7.24
Cash from Operations	4.57
Cash from Investing	-1.34
Cash from Financing	-0.06
Net change in Cash	1.79
Free Cash Flow	4.59

Particulars	MAR 2021 (Values in Cr)
Net Income	-0.17
Cash from Operations	-1.21
Cash from Investing	0.08
Cash from Financing	-0.07
Net change in Cash	-1.20
Free Cash Flow	-0.81

Particulars	MAR 2020 (Values in Cr)
Net Income	0.03
Cash from Operations	0.51
Cash from Investing	3.41
Cash from Financing	-0.08
Net change in Cash	3.49
Free Cash Flow	1.19

Particulars	MAR 2024 (Values in Cr)
Net Income	6.87
Cash from Operations	-5.12
Cash from Investing	-32.31
Cash from Financing	39.18
Net change in Cash	-0.10
Free Cash Flow	-4.56

Particulars	MAR 2023 (Values in Cr)
Net Income	11.91
Cash from Operations	4.66
Cash from Investing	-5.92
Cash from Financing	-0.23
Net change in Cash	-3.62
Free Cash Flow	4.89

Particulars	MAR 2022 (Values in Cr)
Net Income	7.24
Cash from Operations	4.70
Cash from Investing	-1.47
Cash from Financing	-0.06
Net change in Cash	1.79
Free Cash Flow	4.72

Particulars	MAR 2021 (Values in Cr)
Net Income	-0.17
Cash from Operations	-1.54
Cash from Investing	0.42
Cash from Financing	-0.07
Net change in Cash	-1.19
Free Cash Flow	-1.14

Particulars	MAR 2020 (Values in Cr)
Net Income	0.03
Cash from Operations	0.99
Cash from Investing	2.91
Cash from Financing	-0.08
Net change in Cash	3.48
Free Cash Flow	1.68

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
ELPRO INTERNATIONAL LTD.	78.72	16.13	0.65	1334.14	62.30 / 147.70
FORBES & COMPANY LTD.	308.10	14.78	2.15	397.45	264.35 / 796.25
GOLDEN TOBACCO LIMITED	40.25	13.37	-0.33	70.88	36.00 / 60.90
PENINSULA LAND LIMITED	24.40	46.04	2.93	790.56	21.05 / 78.00

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
SANATHNAGAR ENTERPRISES LIMITE	29.92	0.00	-0.73	9.42	25.12 / 87.55
BARODA RAYON CORPORATION LTD.	136.25	20.13	0.90	312.17	120.30 / 215.00
ELPRO INTERNATIONAL LTD.	78.72	21.69	0.68	1334.14	62.30 / 147.70
FORBES & COMPANY LTD.	308.10	13.98	2.77	397.45	264.35 / 796.25

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 26.00
26 Days 25.80
10 Days 25.70
50 Days 26.80
12 Days 25.60
100 Days 28.60
20 Days 25.60
200 Days 30.10

26.28
PIVOT

First Resistance	27.57
Second Resistance	29.16
Third Resistance	30.45

First Support	24.69
Second Support	23.40
Third Support	21.81

RSI	50.68
MACD	-0.16
Commodity Channel Index (CCI)	54.33

ADX	12.68
Williams % R	-42.47

Prerna Infrabuild Ltd. Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

31.42 Promoter Holdings

68.57 FII

0.0 DII

0.0 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
Sanket V Shah (huf)	Shareholding of Promoter and Promoter Group	8083000.0	22.37
Nalini Shah	Shareholding of Promoter and Promoter Group	6564131.0	18.17
Shah Vijay Chandulal (huf)	Shareholding of Promoter and Promoter Group	3881277.0	10.74
Vijay Chandulal Shah	Shareholding of Promoter and Promoter Group	3384771.0	9.37
Swetal Vijay Shah	Shareholding of Promoter and Promoter Group	2447044.0	6.77
Sanket Shah	Shareholding of Promoter and Promoter Group	397404.0	1.1
Niyati Shah	Shareholding of Promoter and Promoter Group	16823.0	0.05

Prerna Infrabuild Ltd.

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type
2011-07-21	0.7	Final	2011-07-25	Equity shares

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read